Inquiry Basket
2'-Modified Nucleosides
(288/288) 3'-Modified Nucleosides
(157/157) 5'-Modified Nucleosides
(236/236) Anhydro-Nucleosides
(13/13) Arabinonucleosides
(34/34) Base Protected Nucleosides
(224/224) Halogen Nucleosides
(134/134) L-Nucleosides
(18/18) Other Nucleosides
(77/77) Other Protected Nucleosides
(23/23) Ribonucleosides
(11/11)
(288/288) 3'-Modified Nucleosides
(157/157) 5'-Modified Nucleosides
(236/236) Anhydro-Nucleosides
(13/13) Arabinonucleosides
(34/34) Base Protected Nucleosides
(224/224) Halogen Nucleosides
(134/134) L-Nucleosides
(18/18) Other Nucleosides
(77/77) Other Protected Nucleosides
(23/23) Ribonucleosides
(11/11)
Backbone
Modification
Base Type
Filtered by
Clear All
3'-O-Methylinosine
Description: 3'-O-Methylinosine is a cutting-edge compound, exhibiting tremendous promise in the research of various diseases. Its therapeutic efficacy stems from its exquisite chemical composition, meticulously designed to selectively target and combat specific drugs or diseases.
CAT: BRP-01705
CAS: 75479-64-0
MF: C11H14N4O5
MF: 282.25
Purity: ≥95%
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.84±0.1 g/cm3
Boiling Point: 724.3±60.0 °C at 760 mmHg
InChIKey: ABXDBVMGRKZFRC-IOSLPCCCSA-N
CanonicalSMILES: COC1C(OC(C1O)N2C=NC3=C2N=CNC3=O)CO
IUPAC Name: 9-[(2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-methoxyoxolan-2-yl]-1H-purin-6-one
InChI: InChI=1S/C11H14N4O5/c1-19-8-5(2-16)20-11(7(8)17)15-4-14-6-9(15)12-3-13-10(6)18/h3-5,7-8,11,16-17H,2H2,1H3,(H,12,13,18)/t5-,7-,8-,11-/m1/s1
Synonyms: 3'-(O-Methyl) Inosine; 3'-O-Methyl-D-inosine; 9-((2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-methoxytetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one; 3'-OMe-I
3'-O-Methyl-5-methylcytidine
Description: 3'-O-Methyl-5-methylcytidine, a remarkable and powerful biomedicine, emerges as an indispensable weapon combating a wide spectrum of afflictions. Its paramount significance permeates the intricate orchestration of cellular dynamics and genetic predisposition. Fashioned with an unparalleled molecular framework, this extraordinary compound unveils a shimmering horizon for revolutionizing cancer therapy, battling relentless viral invasions, and addressing enigmatic autoimmune maladies.
CAT: BRP-01706
CAS: 2086327-74-2
MF: C11H17N3O5
MF: 271.27
Purity: ≥98%
Appearance: White to off-white powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.61±0.1 g/cm3
Boiling Point: 504.6±60.0 °C at 760 mmHg
InChIKey: NQWWPNJIDJMFGO-FDDDBJFASA-N
CanonicalSMILES: CC1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)OC)O
IUPAC Name: 4-amino-1-[(2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-methoxyoxolan-2-yl]-5-methylpyrimidin-2-one
InChI: InChI=1S/C11H17N3O5/c1-5-3-14(11(17)13-9(5)12)10-7(16)8(18-2)6(4-15)19-10/h3,6-8,10,15-16H,4H2,1-2H3,(H2,12,13,17)/t6-,7-,8-,10-/m1/s1
Synonyms: 3'-O-Methyl-5-methyl-D-cytidine; 3'-(O-Methyl)-5-Methyl Cytidine; 4-Amino-5-methyl-1-(3-O-methyl-β-D-xylofuranosyl)-2(1H)-pyrimidinone; 4-amino-1-((2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-methoxytetrahydrofuran-2-yl)-5-methylpyrimidin-2(1H)-one
3'-O-Propargyluridine
Description: 3'-O-Propargyluridine, an exceptional biomedical advancement, emerges as a prominent combatant against formidable viral afflictions like COVID-19. Its unparalleled antiviral capabilities lie in its profound ability to impede the replication of viral RNA. Additionally, this extraordinary compound serves as an invaluable tool for delving into the intricate realm of RNA modifications, RNA labeling, and nucleic acid-based therapeutic methodologies.
CAT: BRP-01707
CAS: 129778-59-2
MF: C12H14N2O6
MF: 282.25
Purity: ≥95%
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.52±0.1 g/cm3
InChIKey: LYDAINNGFSGRDR-QCNRFFRDSA-N
CanonicalSMILES: C#CCOC1C(OC(C1O)N2C=CC(=O)NC2=O)CO
IUPAC Name: 1-[(2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-prop-2-ynoxyoxolan-2-yl]pyrimidine-2,4-dione
InChI: InChI=1S/C12H14N2O6/c1-2-5-19-10-7(6-15)20-11(9(10)17)14-4-3-8(16)13-12(14)18/h1,3-4,7,9-11,15,17H,5-6H2,(H,13,16,18)/t7-,9-,10-,11-/m1/s1
Synonyms: 3'-O-Propargyl-D-uridine; 3'-(O-propargyl) Uridine; 3'-(O-Propargyl)uridine; 1-((2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-(prop-2-yn-1-yloxy)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 3'-O-2-propynyluridine
3'-O-Propargylcytidine
Description: 3'-O-Propargylcytidine, a powerful antiviral agent, is extensively employed to combat various viral infections induced by RNA viruses. By inhibiting viral replication and suppressing viral protein synthesis, this exceptional compound manifests remarkable efficacy against diverse viral strains. Its therapeutic potential has been demonstrated in managing RNA virus-associated disorders, encompassing respiratory tract infections, hepatitis, and influenza.
CAT: BRP-01708
CAS: 1451256-00-0
MF: C12H15N3O5
MF: 281.26
Purity: ≥95%
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.51±0.1 g/cm3
Boiling Point: 544.7±60.0 °C at 760 mmHg
InChIKey: QCHWARZEPUERNY-QCNRFFRDSA-N
CanonicalSMILES: O=C1N=C(N)C=CN1C2OC(CO)C(OCC#C)C2O
IUPAC Name: 4-amino-1-((2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-(prop-2-yn-1-yloxy)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
InChI: InChI=1S/C12H15N3O5/c1-2-5-19-10-7(6-16)20-11(9(10)17)15-4-3-8(13)14-12(15)18/h1,3-4,7,9-11,16-17H,5-6H2,(H2,13,14,18)/t7-,9-,10-,11-/m1/s1
Synonyms: 3'-(O-propargyl) Cytidine; 3'-O-Propargyl-D-cytidine; 3'-O-2-Propyn-1-ylcytidine; 3'-(O-Propargyl)cytidine; 4-amino-1-((2R,3R,4S,5R)-3-hydroxy-5-(hydroxymethyl)-4-(prop-2-yn-1-yloxy)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
5'-DMT-2'-(O-methyl)-guanosine (N-PAC)
Description: 5'-DMT-2'-(O-methyl)-guanosine (N-PAC) is a remarkable pharmacological compound, extensively employed in the research of select malignant neoplasms and viral afflictions. Its formidable inhibitory potential derives from its adeptness at thwarting viral RNA and DNA duplication, effectively thwarting the advance of afflictions birthed by these pathogens.
CAT: BRP-01709
CAS: 138906-94-2
MF: C40H39N5O9
MF: 733.77
Purity: ≥98% by HPLC
Appearance: white crystalline powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.36±0.1 g/cm3
InChIKey: HVGFIPCWVIUNMP-BBKOCAQVSA-N
Solubility: Soluble in acetonitrile
CanonicalSMILES: COC1C(C(OC1N2C=NC3=C2N=C(NC3=O)NC(=O)COC4=CC=CC=C4)COC(C5=CC=CC=C5)(C6=CC=C(C=C6)OC)C7=CC=C(C=C7)OC)O
IUPAC Name: N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxy-3-methoxyoxolan-2-yl]-6-oxo-1H-purin-2-yl]-2-phenoxyacetamide
InChI: InChI=1S/C40H39N5O9/c1-49-28-18-14-26(15-19-28)40(25-10-6-4-7-11-25,27-16-20-29(50-2)21-17-27)53-22-31-34(47)35(51-3)38(54-31)45-24-41-33-36(45)43-39(44-37(33)48)42-32(46)23-52-30-12-8-5-9-13-30/h4-21,24,31,34-35,38,47H,22-23H2,1-3H3,(H2,42,43,44,46,48)/t31-,34-,35-,38-/m1/s1
Synonyms: 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-methyl-N-(2-phenoxyacetyl)guanosine; 5'-DMT-2'-O-Me G(PAC); 5'-DMT-2'-(O-Methyl) Guanosine (n-PAC)
-cytidine-(n-pac).gif)
5'-DMT-2'-(O-methyl)-cytidine (N-PAC)
Description: 5'-DMT-2'-(O-methyl)-cytidine (N-PAC) is a formidable antiviral compound deployed in the research of viral afflictions, with an emphasized efficacy against RNA viruses. Its research of antiviral range expands fervently, encompassing the likes of influenza and hepatitis C.
CAT: BRP-01710
MF: C39H39N3O9
MF: 693.74
Purity: ≥98% by HPLC
Appearance: white crystalline powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
InChIKey: PHESFPHFNNTKHW-QPCXHTPLSA-N
Solubility: Soluble in acetonitrile
IUPAC Name: N-(1-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-2-phenoxyacetamide
InChI: InChI=1S/C39H39N3O9/c1-46-29-18-14-27(15-19-29)39(26-10-6-4-7-11-26,28-16-20-30(47-2)21-17-28)50-24-32-35(44)36(48-3)37(51-32)42-23-22-33(41-38(42)45)40-34(43)25-49-31-12-8-5-9-13-31/h4-23,32,35-37,44H,24-25H2,1-3H3,(H,40,41,43,45)/t32-,35-,36-,37-/m1/s1
Synonyms: 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-methyl-N-(2-phenoxyacetyl)cytidine; 5'-DMT-2'-O-Me C(PAC)
5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine
Description: 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine is a crucial compound used for the research and development of nucleic acid analogs. With its unique chemical structure, it finds application as a building block for modified oligonucleotides. This compound has various potential uses, including the research of viral diseases, cancer and genetic disorders. Its versatile nature makes it an essential tool in drug discovery and the development of targeted therapies.
CAT: BRP-01711
CAS: 644962-77-6
MF: C34H34N2O8
MF: 598.65
Purity: ≥95%
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
InChIKey: LVHXICIDKOYPHH-PBAMLIMUSA-N
CanonicalSMILES: CC#CC1=CN(C(=O)NC1=O)C2C(C(C(O2)COC(C3=CC=CC=C3)(C4=CC=C(C=C4)OC)C5=CC=C(C=C5)OC)O)OC
IUPAC Name: 1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxy-3-methoxyoxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione
InChI: InChI=1S/C34H34N2O8/c1-5-9-22-20-36(33(39)35-31(22)38)32-30(42-4)29(37)28(44-32)21-43-34(23-10-7-6-8-11-23,24-12-16-26(40-2)17-13-24)25-14-18-27(41-3)19-15-25/h6-8,10-20,28-30,32,37H,21H2,1-4H3,(H,35,38,39)/t28-,29-,30-,32-/m1/s1
Synonyms: 5'-DMT-5-Propynyl-2'-(O-Methyl) Uridine; 1-((2R,3R,4R,5R)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)-5-(prop-1-yn-1-yl)pyrimidine-2,4(1H,3H)-dione; Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-methyl-5-(1-propynyl)-
N4-Benzoyl-5'-O-DMT-5-methylcytidine
Description: N4-Benzoyl-5'-O-DMT-5-methylcytidine is an extensively researched biomedical compound, aiding in studying diverse ailments. Its efficacy lies in its capacity to precisely target and modulate RNA and DNA alterations, thereby impeding the growth and propagation of malignant cells.
CAT: BRP-01712
CAS: 160107-17-5
MF: C38H37N3O8
MF: 663.72
Purity: ≥95%
Appearance: White Crystalline Powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Storage: Store at RT
Density: 1.3±0.1 g/cm3
InChIKey: QCKRNDPKDFQXCO-DHKUXYTCSA-N
CanonicalSMILES: CC1=CN(C(=O)N=C1NC(=O)C2=CC=CC=C2)C3C(C(C(O3)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC)O)O
IUPAC Name: N-(1-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-5-methyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide
InChI: InChI=1S/C38H37N3O8/c1-24-22-41(37(45)40-34(24)39-35(44)25-10-6-4-7-11-25)36-33(43)32(42)31(49-36)23-48-38(26-12-8-5-9-13-26,27-14-18-29(46-2)19-15-27)28-16-20-30(47-3)21-17-28/h4-22,31-33,36,42-43H,23H2,1-3H3,(H,39,40,44,45)/t31-,32-,33-,36-/m1/s1
Synonyms: 5'-DMT-5-Methyl Cytidine (n-bz); N4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-5-methylcytidine; N4-Benzoyl-5'-O-dimethoxytrityl-5-methylcytidine; N-(1-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-5-methyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide; 5'-O-(4,4'-dimethoxitrityl)-N-benzoyl-5-methylcytidine; N-Benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-5-methylcytidine
5'-DMT-5-propynyl-uridine
Description: 5'-DMT-5-propynyl-uridine, a modified version of uridine, is a potential therapeutic agent for fighting against neurological diseases including Alzheimer's and Parkinson's. Scientific studies have revealed that it could enhance cognitive function whilst also exhibiting excellent anti-inflammatory properties. With high demand in the biomedical industry, this product holds great promise for those looking to alleviate the negative effects of these devastating diseases.
CAT: BRP-01713
CAS: 644962-76-5
MF: C33H32N2O8
MF: 584.62
Purity: ≥98% by HPLC
Appearance: white crystalline powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
InChIKey: VFKJTINFVHDNPY-BUVRPPHQSA-N
Solubility: Soluble in acetonitrile
CanonicalSMILES: CC#CC1=CN(C(=O)NC1=O)C2C(C(C(O2)COC(C3=CC=CC=C3)(C4=CC=C(C=C4)OC)C5=CC=C(C=C5)OC)O)O
IUPAC Name: 1-[(2R,3R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3,4-dihydroxyoxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione
InChI: InChI=1S/C33H32N2O8/c1-4-8-21-19-35(32(39)34-30(21)38)31-29(37)28(36)27(43-31)20-42-33(22-9-6-5-7-10-22,23-11-15-25(40-2)16-12-23)24-13-17-26(41-3)18-14-24/h5-7,9-19,27-29,31,36-37H,20H2,1-3H3,(H,34,38,39)/t27-,28-,29-,31-/m1/s1
Synonyms: 5'-O-[Bis(4-methoxyphenyl)(phenyl)methyl]-5-prop-1-yn-1-yluridine; 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-5-(1-propyn-1-yl)uridine; Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-5-(1-propynyl)-; 5'-DMT-5-Propynyl Uridine
2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine
Description: 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine, a compound hailed within the biomedical industry, exhibiting intriguing medicinal potential. It serves as a catalyst in the creation of tailored therapeutics, meticulously designed to thwart precise pathways by selectively maneuvering functions.
CAT: BRP-01714
CAS: 869354-79-0
MF: C39H45N7O7
MF: 723.84
Purity: ≥97%
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.29±0.1 g/cm3
InChIKey: HUYROJQAEKXGHQ-GONXPTGJSA-N
CanonicalSMILES: CC(C)C(=O)NC1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC)O)OC)N=CN(C)C
IUPAC Name: N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxy-3-methoxyoxolan-2-yl]-6-(dimethylaminomethylideneamino)purin-2-yl]-2-methylpropanamide
InChI: InChI=1S/C39H45N7O7/c1-24(2)36(48)44-38-42-34(41-22-45(3)4)31-35(43-38)46(23-40-31)37-33(51-7)32(47)30(53-37)21-52-39(25-11-9-8-10-12-25,26-13-17-28(49-5)18-14-26)27-15-19-29(50-6)20-16-27/h8-20,22-24,30,32-33,37,47H,21H2,1-7H3,(H,42,43,44,48)/t30-,32-,33-,37-/m1/s1
Synonyms: Adenosine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-N-[(dimethylamino)methylene]-2'-O-methyl-2-[(2-methyl-1-oxopropyl)amino]-; N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)-6-(((dimethylamino)methylene)amino)-9H-purin-2-yl)isobutyramide; 2'-OMe-5'-DMT-2,6-diamino purine riboside (n6,n6-dmf) (n2-ibu); 2'-OMe-5'-DMT-N2-amino-ibu rA(N6-DMF)
5'-O-DMT-N6-(2-phenoxyacetyl)-adenosine
Description: 5'-O-DMT-N6-(2-phenoxyacetyl)-adenosine, a biomedical marvel, takes the forefront in combating a myriad of ailments. Amplifying its potential as an adenosine receptor modulator, it possesses the prowess to intricately manage neurological disorders, cardiac conditions, and inflammatory diseases. Its distinctive chemical structure intertwines with its pharmacological properties, propelling it to the forefront of future biomedical investigations.
CAT: BRP-01715
CAS: 121076-16-2
MF: C39H37N5O8
MF: 703.74
Purity: ≥95%
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.36±0.1 g/cm3 (Predicted)
InChIKey: GWFRSQBGIGLMFD-BBKOCAQVSA-N
CanonicalSMILES: COC1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)OC)OCC4C(C(C(O4)N5C=NC6=C(N=CN=C65)NC(=O)COC7=CC=CC=C7)O)O
IUPAC Name: N-[9-[(2R,3R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3,4-dihydroxyoxolan-2-yl]purin-6-yl]-2-phenoxyacetamide
InChI: InChI=1S/C39H37N5O8/c1-48-28-17-13-26(14-18-28)39(25-9-5-3-6-10-25,27-15-19-29(49-2)20-16-27)51-21-31-34(46)35(47)38(52-31)44-24-42-33-36(40-23-41-37(33)44)43-32(45)22-50-30-11-7-4-8-12-30/h3-20,23-24,31,34-35,38,46-47H,21-22H2,1-2H3,(H,40,41,43,45)/t31-,34-,35-,38-/m1/s1
Synonyms: 5'-DMT Adenosine (n-PAC); 5'-O-(4,4'-Dimethoxytrityl)-N6-phenoxyacetyl adenosine; 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-N6-(2-phenoxyacetyl)adenosine; N-(Phenoxyacetyl)-5'-O-(4,4'-dimethoxytrityl)adenosine; N-(9-((2R,3R,4S,5R)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)-2-phenoxyacetamide; 5'-O-[Bis(4-methoxyphenyl)(phenyl)methyl]-N-(phenoxyacetyl)adenosine
7-Deazainosine
Description: 7-Deazainosine is a modified nucleoside derivative that is used in RNA and DNA research. It is a modified form of adenosine where the nitrogen at the 7-position of the purine ring is replaced by a carbon atom. This modification alters the base-pairing properties of the nucleoside, making it useful for studying RNA folding and interactions. Additionally, 7-Deazainosine can also be incorporated into synthetic oligonucleotides for various applications in molecular biology and biotechnology.
CAT: BRP-01717
CAS: 2862-16-0
MF: C11H13N3O5
MF: 267.24
Purity: 95%
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.90±0.1 g/cm3
Melting Point: 240 °C
Boiling Point: 679.7±55.0 °C at 760 mmHg
InChIKey: DPRSKJHWKNHBOW-KCGFPETGSA-N
CanonicalSMILES: C1=CN(C2=C1C(=O)NC=N2)C3C(C(C(O3)CO)O)O
IUPAC Name: 7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-pyrrolo[2,3-d]pyrimidin-4-one
InChI: InChI=1S/C11H13N3O5/c15-3-6-7(16)8(17)11(19-6)14-2-1-5-9(14)12-4-13-10(5)18/h1-2,4,6-8,11,15-17H,3H2,(H,12,13,18)/t6-,7-,8-,11-/m1/s1
Synonyms: 7-Deaza ribo Inosine; 3,7-Dihydro-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one; 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-β-D-ribofuranosyl-; 7-(β-D-Ribofuranosyl)pyrrolo[2,3-d]pyrimidin-4-one; 7-β-D-Ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol; Antibiotic XK 101-2; NSC 99439
7-Deazaguanosine
Description: It is a guanosine analogue with antiviral and anti-HCV activity.
CAT: BRP-01718
CAS: 62160-23-0
MF: C11H14N4O5
MF: 282.25
Purity: ≥95%
Appearance: Off-white Solid
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Storage: Store at -20°C under inert atmosphere
Density: 2.06±0.1 g/cm3 (Predicted)
Melting Point: >250°C (dec.)
Boiling Point: 668.3±65.0°C at 760 mmHg
InChIKey: JRYMOPZHXMVHTA-DAGMQNCNSA-N
Solubility: Soluble in Methanol
CanonicalSMILES: C1=CN(C2=C1C(=O)NC(=N2)N)C3C(C(C(O3)CO)O)O
IUPAC Name: 2-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-pyrrolo[2,3-d]pyrimidin-4-one
InChI: InChI=1S/C11H14N4O5/c12-11-13-8-4(9(19)14-11)1-2-15(8)10-7(18)6(17)5(3-16)20-10/h1-2,5-7,10,16-18H,3H2,(H3,12,13,14,19)/t5-,6-,7-,10-/m1/s1
Synonyms: 7-Deaza ribo Guanosine; 2-Amino-7-(β-D-ribofuranosyl)-1,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one; 2-Amino-1,7-dihydro-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one; 2-Amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one; N7-Deazaguanosine
β-L-Adenosine
Description: β-L-Adenosine is a versatile biochemical compound extensively employed in the biomedical sector for advanced research studies, showcasing a profound significance in probing its exceptional efficacy against a gamut of ailments, including cancer, viral infections, as well as autoimmune disorders.
CAT: BRP-01727
CAS: 3080-29-3
MF: C10H13N5O4
MF: 267.24
Purity: ≥97% by HPLC
Appearance: White Crystalline Powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Storage: Store at -20°C
Density: 2.08±0.1 g/cm3 (Predicted)
Melting Point: 219-224°C
Boiling Point: 676.3±65.0°C (Predicted)
InChIKey: OIRDTQYFTABQOQ-DEGSGYPDSA-N
Solubility: Soluble in DMSO (Slightly), Methanol (Slightly, Heated)
CanonicalSMILES: C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N
IUPAC Name: (2S,3S,4R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
InChI: InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m0/s1
Synonyms: Beta-L-ribo Adenosine; L-Adenosine; L-rA; Beta-L-adenosine; (2S,3S,4R,5S)-2-(6-Amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 9-beta-L-Ribofuranosyladenine; 9-(b-L-Ribofuranosyl)adenine; 9-beta-L-Ribofuranosyl-9H-purine-6-amine
L-Cytidine
Description: L-Cytidine is a prominent bioactive compound employed extensively, emerging as a pivotal compound for the genesis of nucleic acids. Exerting a profound influence on cellular metabolism, it assumes a crucial mantle in studying diverse ailments encompassing viral afflictions, malignant neoplasms and conditions affecting the neurologic milieu.
CAT: BRP-01728
CAS: 26524-60-7
MF: C9H13N3O5
MF: 243.22
Purity: ≥97% by HPLC
Appearance: White to Off-white Solid
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Storage: Store at 2-8°C
Density: 1.89±0.1 g/cm3
Boiling Point: 545.7±60.0 °C at 760 mmHg
InChIKey: UHDGCWIWMRVCDJ-PSQAKQOGSA-N
CanonicalSMILES: C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
IUPAC Name: 4-amino-1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
InChI: InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m0/s1
Synonyms: Beta-L-ribo Cytidine; beta-L-Cytidine; 4-Amino-1-((2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 1-beta-L-Ribofuranosylcytosine; L-rC; 2(1H)-Pyrimidinone, 4-amino-1-beta-L-ribofuranosyl-; 4-Amino-1-(β-L-ribofuranosyl)-2(1H)-pyrimidinone; β-L-Cytidine
L-Uridine
Description: L-Uridine, a crucial nucleoside component harnessed for its role in promoting protein synthesis, boasts neuroprotective abilities, demonstrated in its function as a potent inhibitor of neuronal death while concurrently elevating neuroplasticity. Exhibiting efficacy in treating neurodegenerative ailments such as Alzheimer's and Parkinson's disease, L-Uridine further improves cognitive functions and memory. Its diverse range extends to addressing certain types of cancer and viral infections, positioning it to be a burgeoning therapeutic marvel.
CAT: BRP-01730
CAS: 26287-69-4
MF: C9H12N2O6
MF: 244.20
Purity: ≥99% by HPLC
Appearance: White to off-white crystalline powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Storage: Store at 2-8°C
Density: 1.674±0.06 g/cm3
InChIKey: DRTQHJPVMGBUCF-PSQAKQOGSA-N
CanonicalSMILES: C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O
IUPAC Name: 1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
InChI: InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m0/s1
Synonyms: Beta-L-ribo Uridine; 1-(b-L-ribofuranosyl)uracil; 1-((2S,3S,4R,5S)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-β-L-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione; Uracil, 1-β-L-ribofuranosyl-; β-L-Uridine
L-Inosine
Description: L-Inosine is a pivotal nucleoside, showcasing indispensible involvement in energy metabolism and purine nucleotide synthesis. Its profound significance thrives in the biomedical sector, where it acts as a adjunct for studying multifarious ailments such as immune-related disorders, neurodegenerative afflictions and cardiovascular maladies.
CAT: BRP-01731
CAS: 21138-24-9
MF: C10H12N4O5
MF: 268.23
Purity: ≥97% by HPLC
Appearance: Off-white Powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Storage: Store at -20°C
Density: 2.08 g/cm3
Melting Point: 218 °C
Boiling Point: 797.9±60.0 °C(Predicted)
InChIKey: UGQMRVRMYYASKQ-DEGSGYPDSA-N
CanonicalSMILES: C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O
IUPAC Name: 9-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
InChI: InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m0/s1
Synonyms: Beta-L-ribo Inosine; 9-((2S,3S,4R,5S)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; 9-beta-L-Ribofuranosylhypoxanthine; L-ribofuranosyl-Inosine; 1,9-Dihydro-9-β-L-ribofuranosyl-6H-purin-6-one; Hypoxanthine, 9-β-L-ribofuranosyl-; 9-(β-L-Ribofuranosyl)-3,9-dihydro-6H-purin-6-one; β-L-Inosine
1,N6-Ethenoadenosine
Description: N6-Ethenoadenosine, a purine nucleoside analog, is paramount for the examination of oxidative damage on cellular DNA. It has demonstrated a capability to initiate DNA damage and apoptosis in cancer cells, rendering it an integral component of investigating its effectiveness as an anticancer agent. Its potential usage within the realm of cancer treatment necessitates a thorough understanding and exploration of its capabilities.
CAT: BRP-01732
CAS: 39007-51-7
MF: C12H13N5O4
MF: 291.26
Purity: ≥95% by HPLC
Appearance: White to Brown Crystalline Powder
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Storage: Store at -20°C
Density: 1.99±0.1 g/cm3
InChIKey: LRPBXXZUPUBCAP-WOUKDFQISA-N
CanonicalSMILES: C1=CN2C=NC3=C(C2=N1)N=CN3C4C(C(C(O4)CO)O)O
IUPAC Name: (2R,3S,4R,5R)-2-(hydroxymethyl)-5-imidazo[2,1-f]purin-3-yloxolane-3,4-diol
InChI: InChI=1S/C12H13N5O4/c18-3-6-8(19)9(20)12(21-6)17-5-14-7-10-13-1-2-16(10)4-15-11(7)17/h1-2,4-6,8-9,12,18-20H,3H2/t6-,8-,9-,12-/m1/s1
Synonyms: Etheno ribo Adenosine; N6-Etheno-D-adenosine; N6-Ethenoadenosine; 3-(β-D-Ribofuranosyl)-3H-imidazo[2,1-i]purine; (2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(3H-imidazo[2,1-i]purin-3-yl)tetrahydrofuran-3,4-diol; 3-β-D-Ribofuranosyl-3H-imidazo[2,1-i]purine; 1,6-Ethenoadenosine; Ethenoadenosine; N6-β-D-Ribosyl-1,N6-ethenoadenine; ε-Adenosine
N4-Ethenocytidine
Description: N4-Ethenocytidine, an indispensable compound within the biomedical industry, is of paramount significance. Its idiosyncratic molecular architecture renders it an ideal candidate for comprehensive research endeavors focusing on elucidating the intricate mechanisms underlying DNA methyltransferases' regulation and functionality. Profound insights gained from such investigations facilitate a holistic comprehension of the fundamental aspects of epigenetic modifications.
CAT: BRP-01733
CAS: 39007-52-8
MF: C11H13N3O5
MF: 267.24
Purity: ≥98% by HPLC
Appearance: White to off-white solid
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Density: 1.82±0.1 g/cm3
Boiling Point: 657.4±65.0 °C at 760 mmHg
InChIKey: DUCZQUFMCSTEHH-PEBGCTIMSA-N
CanonicalSMILES: C1=CN(C(=O)N2C1=NC=C2)C3C(C(C(O3)CO)O)O
IUPAC Name: 6-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[1,2-c]pyrimidin-5-one
InChI: InChI=1S/C11H13N3O5/c15-5-6-8(16)9(17)10(19-6)14-3-1-7-12-2-4-13(7)11(14)18/h1-4,6,8-10,15-17H,5H2/t6-,8-,9-,10-/m1/s1
Synonyms: Etheno ribo Cytidine; N4-Etheno-D-cytidine; Ethenocytidine; 6-β-D-Ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-one; 3,N4-Ethenocytidine
2,2'-Anhydrocytidine
Description: 2,2'-Anhydrocytidine, an intriguing compound highly regarded in the biomedical field, serves as a critical subject of research owing to its profound prospects in combatting viral infections, especially those instigated by RNA viruses.
CAT: BRP-01734
CAS: 31698-14-3
MF: C9H11N3O4
MF: 225.20
Purity: ≥95%
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | -- | -- |
Storage: Store at -20°C
Density: 2.01±0.1 g/cm3
Melting Point: 249°C (dec.)
Boiling Point: 422.2±55.0°C at 760 mmHg
InChIKey: BBDAGFIXKZCXAH-CCXZUQQUSA-N
Solubility: Soluble in Methanol (Slightly), Water (Sparingly)
CanonicalSMILES: C1=CN2C3C(C(C(O3)CO)O)OC2=NC1=N
IUPAC Name: (2R,4R,5R,6S)-4-(hydroxymethyl)-10-imino-3,7-dioxa-1,9-diazatricyclo[6.4.0.02,6]dodeca-8,11-dien-5-ol
InChI: InChI=1S/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2/t4-,6-,7+,8-/m1/s1
Synonyms: 6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, (2R,3R,3aS,9aR)-; (2R,3R,3aS,9aR)-2,3,3a,9a-Tetrahydro-3-hydroxy-6-imino-6H-furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol; 6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, [2R-(2α,3β,3aβ,9aβ)]-; 6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, stereoisomer; 2,2'-Anhydro(1-β-D-arabinofuranosyl)cytosine; 2,2'-Anhydroarabinosylcytosine; 2,2'-Cyclocytidine; 2,2'-O-Cyclocytidine; Ancitabine; Ancytabine; Cyclocytidine; O2,2'-Cyclocytidine; O2:2'-Anhydro-1-β-D-arabinosylcytosine
Related CAS: 34939-46-3 (Deleted CAS) ; 36258-39-6 (Deleted CAS) ; 46488-37-3 (Deleted CAS) ; 51743-54-5 (Deleted CAS) ; 10212-25-6 (monohydrochloride)
